Anna Richo - UCB SA Executive VP and General Counsel
| UCBJY Stock | USD 65.26 0.33 0.51% |
EVP
Ms. Anna S. Richo has served as Executive Vice President, General Counsel, Member of the Executive Committee of UCB S.A. since November 1, 2012. She joined the Company on November 1, 2012. She joined UCB from Amgen Inc., where she was Senior Vice President and Chief Compliance Officer. Prior to that, she was Vice President, Law responsible for management of Amgens corporate litigation and law department operations, and upon joining Amgen in 2003, she was responsible for corporate law activities. From 1991 2003, she was at Baxter Healthcare Corporationrationration, holding a number of positions with increasing responsibility including Vice President, Law for the Bio Science business and was previously Chief Litigation Counsel for the company. Prior to joining Baxter, Ms. Richo was an attorney for The NutraSweet Company, and was an associate with the Chicagobased law firm of Peterson Ross since 2012.
| Age | 58 |
| Tenure | 12 years |
| Phone | 32 2 559 99 99 |
| Web | https://www.ucb.com |
UCB SA Management Efficiency
The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0468 |
UCB SA ADR Leadership Team
Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee | ||
| Detlef Thielgen, CFO and Executive VP | ||
| Kay Davies, Independent Director | ||
| Dirk Teuwen, VP Corporate Societal Responsibility | ||
| Anna Richo, Executive VP and General Counsel | ||
| Viviane Monges, Independent Non-Executive Director | ||
| Gerhard Mayr, Non-Executive Chairman of the Board | ||
| Cyril Janssen, Director | ||
| Caroline Vancoillie, Chief Functions | ||
| Cedric Rijckevorsel, Director | ||
| JeanChristophe Tellier, Chairman of the Executive Committee, CEO | ||
| Arnoud Calesberg, Non-Executive Director | ||
| Mark McDade, COO and Executive VP | ||
| Xavier Michel, Vice President and Secretary General | ||
| Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee | ||
| Bharat Tewarie, Executive Vice President Chief Marketing Officer | ||
| Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director | ||
| Norman Ornstein, Non-Executive Independent Director | ||
| Jeff Wren, Executive Vice President Neurology – Patient Value Unit Head | ||
| JeanPierre Kinet, Non-Executive Independent Director | ||
| Antje Witte, VP of Investor Relations | ||
| Alice Dautry, Independent Director | ||
| Sandrine CFA, Ex CFO | ||
| Harriet Edelman, Non-Executive Independent Director | ||
| Ulf Wiinberg, Independent Director | ||
| William Silbey, Exec Counsel | ||
| Thomas McKillop, Non-Executive Independent Director | ||
| Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee | ||
| France Nivelle, VP Global Communication | ||
| Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee | ||
| Pierre Gurdjian, Independent Director | ||
| Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP | ||
| Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head | ||
| Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board | ||
| Iris LoewFriedrich, Executive Vice President Chief Medical Officer | ||
| CharlesAntoine Janssen, Non-Executive Director | ||
| Pr LowFriedrich, Chief VP | ||
| Kirsten LundJurgensen, Ex Solutions | ||
| Albrecht Graeve, Non-Executive Independent Director | ||
| JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee | ||
| Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee |
UCB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0468 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 16.62 B | |||
| Shares Outstanding | 379.92 M | |||
| Price To Earning | 17.55 X | |||
| Price To Book | 1.55 X | |||
| Price To Sales | 2.54 X | |||
| Revenue | 5.78 B |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards UCB SA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, UCB SA's short interest history, or implied volatility extrapolated from UCB SA options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UCB SA ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in inflation. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for UCB Pink Sheet analysis
When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |